Ci-1040
A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.
What it is
CI-1040 is a small molecule MEK inhibitor that targets the mitogen-activated protein kinase (MAPK) pathway in colorectal cancer treatment. This compound specifically inhibits MEK1 and MEK2 kinases, which are critical components of the RAS/RAF/MEK/ERK signaling cascade frequently dysregulated in colorectal malignancies. CI-1040 was developed to block tumor cell proliferation and survival signals in advanced colorectal cancer patients, particularly those with RAS pathway mutations.
How it works
CI-1040 works by selectively binding to and inhibiting MEK1 and MEK2 kinases, preventing the phosphorylation and activation of downstream ERK1/2 proteins. This inhibition disrupts the RAS/RAF/MEK/ERK signaling pathway, leading to decreased tumor cell proliferation, increased apoptosis, and reduced angiogenesis in colorectal cancer cells with aberrant MAPK pathway activation.
Molecular targets
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Guides that may help
Written for patients and families, in plain language.